June 2023
-
06.26.2023
Research and Pipeline Research Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
-
06.23.2023
Prescription Medicines Medicines FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
-
06.22.2023
Financial Finance Pfizer Declares Third-Quarter 2023 Dividend
-
06.20.2023
Prescription Medicines Medicines Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
-
06.20.2023
-
06.06.2023
-
06.01.2023
May 2023
-
05.31.2023
-
05.30.2023
-
05.25.2023
-
05.25.2023
-
05.18.2023